Blog
Get the latest news about liver diseases and more
Get the latest news about liver diseases and more
A promising new treatment for fatty liver disease has outperformed existing medications like Ozempic and Mounjaro in reducing liver fat, according to a recent study presented at a major liver disease conference.
Hepalatide, used with pegylated interferon-alpha, shows promise for curing chronic hepatitis B by eliminating cccDNA from liver cells, according to early study results presented in a European liver congress.
Resmetirom is the first approved drug for steatohepatitis, effective in reducing liver fat and fibrosis. Available in the U.S., it awaits approval in Europe due to high cost and limited access.
Efimosfermin-alfa shows promise as a treatment for fatty liver disease, improving fibrosis and inflammation with monthly dosing, according to early clinical study results.
A JAMA study shows that statins may benefit liver disease patients by lowering liver cancer risk, reducing complications, and improving fibrosis, especially with lipophilic and hydrophilic statins.
Fatty liver disease prevention involves healthy diets, intermittent fasting, regular exercise, coffee intake, and limiting sugars and saturated fats. These actions help reduce liver fat and disease risk.
Research indicates a potential relationship between fatty liver, kidney stones, and gallstones due to shared metabolic risk factors. More studies are required to validate these findings across different populations.
Studies suggest that curcumin for fatty liver improves liver enzyme levels, reduces fibrosis, and has cardiovascular benefits. Although promising, more extensive trials are needed to validate its effectiveness as a long-term treatment option.
29 de March de 2019
18 de November de 2021
2 de July de 2023